Free Trial
ASX:LCT

Living Cell Technologies (LCT) Stock Price, News & Analysis

Living Cell Technologies logo

About Living Cell Technologies Stock (ASX:LCT)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
76,622 shs
Average Volume
N/A
Market Capitalization
$24.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in Australia and New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson's disease. The company was founded in 1987 and is based in Melbourne, Australia.

Receive LCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Living Cell Technologies and its competitors with MarketBeat's FREE daily newsletter.

LCT Stock News Headlines

Mysterious stem cells: LCT procedure (3)
Nvidia’s Next Big Move Comes on Feb. 26
Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of companies partnering with Nvidia on its latest AI Superproject … Companies we refer to as Nvidia's "Silent Partners" … And they could benefit greatly as well on Feb. 26.
Living Cell Technologies Announces Director’s Interest Change
See More Headlines

LCT Stock Analysis - Frequently Asked Questions

Living Cell Technologies Limited (ASX:LCT) released its quarterly earnings results on Tuesday, February, 19th. The company reported $0.00 earnings per share for the quarter.

Based on aggregate information from My MarketBeat watchlists, some other companies that Living Cell Technologies investors own include eWellness Healthcare (EWLL), Energous (WATT), Cheniere Energy (LNG) and AllianceBernstein Global High Income Fund (AWF).

Company Calendar

Last Earnings
2/19/2019
Today
2/23/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
147,000
Year Founded
N/A

Profitability

Net Income
$-2,110,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3,405.00

Miscellaneous

Outstanding Shares
1,640,000,000
Free Float
N/A
Market Cap
$24.53 million
Optionable
Not Optionable
Beta
0.48
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (ASX:LCT) was last updated on 2/23/2025 by MarketBeat.com Staff
From Our Partners